Population pharmacokinetic and pharmacodynamic analysis of bosutinib (Q44833185)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

6 December 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Population pharmacokinetic and pharmacodynamic analysis of bosutinib (English)

1 reference

6 December 2017

1 reference

1 reference

Poe-Hirr Hsyu

1

1 reference

6 December 2017

Diane R Mould

series ordinal

2

1 reference

6 December 2017

Richat Abbas

series ordinal

3

1 reference

6 December 2017

Michael Amantea

series ordinal

4

1 reference

6 December 2017

publication date

10 June 2014

1 reference

Drug Metabolism and Pharmacokinetics

6 December 2017

published in

1 reference

6 December 2017

volume

29

1 reference

6 December 2017

issue

6

1 reference

6 December 2017

page(s)

441-448

1 reference

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.

6 December 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.2133/DMPK.DMPK-13-RG-126

Identifiers

DOI

10.2133/DMPK.DMPK-13-RG-126

1 reference

6 December 2017

1 reference